Clinical Trials in Mumbai, India
75 recruiting
Showing 1–20 of 182 trials
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled301 locationsNCT06692738
Recruiting
Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled205 locationsNCT05827081
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled192 locationsNCT05894239
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
AstraZeneca5,000 enrolled759 locationsNCT06742723
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled254 locationsNCT07361497
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled299 locationsNCT06561386
Recruiting
Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled371 locationsNCT06238622
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 3
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Non-small Cell Lung Cancer (NSCLC)
AstraZeneca400 enrolled204 locationsNCT07291037
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC520 enrolled156 locationsNCT06305754
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled228 locationsNCT06935357
Recruiting
Phase 2Phase 3
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
Active Immunisation for Chikungunya Virus Infection
Bharat Biotech International Limited1,000 enrolled10 locationsNCT07555392
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled215 locationsNCT06345729
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.630 enrolled351 locationsNCT06875310
Recruiting
Phase 2Phase 3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Metastatic Pancreatic Ductal AdenocarcinomaCachexia
Pfizer982 enrolled114 locationsNCT06989437
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Hemophilia
Sanofi85 enrolled21 locationsNCT07285460
Recruiting
Phase 3
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled190 locationsNCT04892173
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled318 locationsNCT06528314
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280